A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2
mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and
activity rules. Subjects will be confined on either days 1-3 and/or days 8-10. Follow-up
visits are also required periodically through day 43. Study procedures involve taking blood
samples for pharmacokinetic, pharmacodynamic, virologic, and safety assessments.